Patents Assigned to Selexs S.A.
  • Patent number: 12404527
    Abstract: Type-C endogenous retroviruses (ERVs) embedded in Chinese hamster ovary (CHO) cells were altered to modify the release of retroviral and/or retroviral-like particles in the culture supernatant. Although evidence for the infectivity of these particles is missing, their presence has raised safety concerns. 173 type-C ERV sequences that clustered into functionally conserved groups were identified. Transcripts from one type-C ERV group were identified to be full-length with intact open reading frames, and to have corresponding viral RNA genomes that were loaded into retroviral-like particles. Also, sequence analysis of the genomic RNA from viral particles indicated that they may result from few expressed ERV sequences. Disclosed herein is the disruption/alteration of the gag gene of the expressed ERV group using CRISPR-Cas9 genome editing.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 2, 2025
    Assignee: Selexs S.A.
    Inventors: Pierre-Olivier Duroy, Sandra Bosshard, Philippe Le Mercier, Emanuel Schmid-Siegert, Nicolas Mermod